Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Increase in Short InterestTicker Report • 24 days ago
Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,120,000...
Share to Feed
HC Wainwright restated their buy rating on shares of Ikena Oncology (NASDAQ:IKNA Free Report) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has...
Ikena Oncology (NASDAQ:IKNA Get Free Report)s stock had its buy rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They...
Latest Ratings for IKNA
DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021Credit SuisseMaintainsOutperform Apr 2021JefferiesInitiates Coverage OnBuy
View More...
Ikena Oncology, Inc. (NASDAQ:IKNA Free Report) Investment analysts at William Blair cut their Q1 2024 EPS estimates for Ikena Oncology in a research report issued on Tuesday, March...
Ikena Oncology (NASDAQ:IKNA Get Free Report)s stock had its outperform rating reissued by Wedbush in a research note issued to investors on Tuesday, RTT News reports...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in...
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena, Company ), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development...
Ikena Oncology (NASDAQ:IKNA Get Free Report)s stock had its outperform rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on...